das Durchschnittsziel auf 41.06$ (Yahoo)
|
heute wurde noch etwa 7 mio Aktien gehandelt ca 1/2 des normalen Durchschnittes.
Wahrscheinlich haben div (Hedge)Fonds den schnellen Gewinn realisiert.
Trotzdem gibt's auch die gute Sicht: investorplace.com/2017/02/...eva-turning-around/#.WKdtTPnhD50
Date Closing Price (0.01 NIS) Change (%) Base Price Opening Price High Low Turnover (NIS)
19/02/2017§13,750 ¨¨¨¨¨¨¨¨¨¨¨¨¨¨¨¨¨¨2.69%¨¨¨¨¨¨¨¨¨¨¨¨¨¨¨¨13,390¨¨¨¨¨¨¨¨¨¨¨¨¨¨13,550¨¨¨¨¨¨¨13,800¨13,470 64,262,920
Bald kommt die Wende nach oben !
Grossinvestoren kaufen (Fidelity hat etwas verkauft).
The largest institutional investor in Teva is Fidelity, which held 6.2% of the company at the beginning of 2017. Fidelity actually sold 4.5 million shares in the fourth quarter of 2016, whereas Capital Research Global Investments, Barrow Hanley Mewhinney & Strauss, and The Bank of New York Mellon, the four largest shareholders after Fidelity, bought an aggregate 42 million shares. It appears that most of the institutions expect a positive return on the stock.
The Cautious Bull Case for TEVA Stock
Lau is an optimist, and for good reason. For starters, the market price for TEVA stock is at levels not seen since late 2013. As a result of the massive fallout, the forward-price-earnings ratio for Teva Pharmaceutical is less than 8. That’s absurdly below the pharma industry’s median forward P/E ratio of 14.7. (investorplace.com)
in USA Pre-market: 37.48 +2.28 (6.48%) :-)
dies scheint keine Negativauswirkungen auf den Kurs zu haben (wurde wohl in den letzten Tagen vorweg genommen).
Teva Pharmaceutical goes ex-dividend tomorrow
Feb. 27, 2017 6:49 AM ET|About: Teva Pharmaceutical Industries Limited (TEVA)
Teva Pharmaceutical (NYSE:TEVA) had declared $0.34/share quarterly dividend, in line with previous.
Payable March 20; for shareholders of record March 2; ex-div Feb. 28.
Teva launches generic Pristiq in U.S.
Mar. 1, 2017 11:20 AM ET|About: Teva Pharmaceutical In... (TEVA)|By: Douglas W. House, SA News Editor
Teva Pharmaceutical Industries (TEVA +0.2%) launches its generic version of Pfizer's (PFE +1%) antidepressant Pristiq (desvenlafaxine) in the U.S.
According to IMS, Pristiq's American sales are ~$883M per year.
mal schauen, ob Trump was dagegen hat ?
in der Pipeline scheint schon noch was bereit zu sein.
An application for a new drug by Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has been accepted by the Food and Drug Administration. Teva’s drug that is used to treat tardive dyskinesia, SD-809, has also been given priority review. This will allow the drug to be evaluated at a faster rate.
Teva Pharmaceuticals (TEVA) ist eines der 40 Unternehmen, die für angebliche Preisfestsetzung verklagt werden. Die Aktie, die in der Nähe eines 10-Jahres-Tiefes, wahrscheinlich in allen schlechten Nachrichten voraus.
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
12 | 4.438 | TEVA -- Zukunft mit Generika | 14051948Kibbuzim | Bishop of Diebach | 10.05.24 10:44 | |
89 | Bausch Health - ehemals Valeant - u.a. Pharmawerte | macumba | newson | 29.07.22 10:39 | ||
32 | Der Parkinson Thread | geldschneider | Bilderberg | 18.12.17 09:00 | ||
1 | Teva kann Gewinn im zweiten Quartal verdoppeln... | wehai | gogol | 27.02.09 17:43 | ||
3 | 7 | Teva: Chancen und Risiken bei Generika | Blaumeise | skunk.works | 02.05.07 13:57 |